Is Panobinostat available in China?

Panobinostat (Panobinostat) is a histone deacetylase inhibitor that is widely used in the treatment of multiple myeloma. Its main mechanism is to block the growth and spread of cancer cells by inhibiting the activity of histone deacetylase and regulating gene expression.

Panobinostat is not currently on the market in China, so patients cannot purchase it domestically and need to purchase panobinostat through overseas channels. There are only panobinostat original drugs available abroad, mainly the European version of the Swiss Novartis original drug, which is expensive, as high as more than 40,000 yuan.

As a new type of anti-cancer drug, panobinostat exhibits excellent anti-cancer effects through multiple effects. First, it can induce the apoptosis of tumor cells and promote the spontaneous death of abnormally proliferated plasma cells, thereby inhibiting the growth of tumor cells. Secondly, by inhibiting angiogenesis and reducing the blood supply to tumors, it effectively curbs the nutrient source of cancer cells. Most importantly, panobinostat has shown significant efficacy in patients with multiple myeloma, especially those who have failed previous treatments, providing a new treatment option for this specific patient group.

However, the use of panobinostat is also associated with some adverse reactions, including hematological toxicity, cardiotoxicity, and gastrointestinal reactions. Therefore, when applying this drug, doctors need to carefully assess the patient's physical condition and conduct close monitoring to ensure optimal therapeutic effects while minimizing adverse effects.

In general, panobinostat, as an innovative anti-cancer drug, provides a new treatment option for patients with multiple myeloma, and also provides a useful reference for research and development in related fields.